Molecule

CurePSP Awards Latest Pathway and Pipeline Grants and Urso Student Fellowship Grants Looking to Take Advantage of Recent Neuroscience Breakthroughs

Retrieved on: 
Thursday, September 28, 2023
Molecule, Columbia University, Translation, Mario Negri Institute for Pharmacological Research, Columbia University Irving Medical Center, Database, Pedunculopontine nucleus, University, Cell death, Therapy, Icahn School of Medicine at Mount Sinai, Stanford University, Epidemiology, Incyte, Role, ISR, Progressive supranuclear palsy, Allied Social Science Associations, Rossy, Research, Brain, Mount Sinai, Biomarker, Tauopathy, Neuron, Student, Patient, Pharmacological Research, SUNY, Integrated stress response, Neuroscience, CBD, Mouse, Diagnosis, Cognitive neuroscience, Gene, TIA1, Alzheimer's disease, PSP, Nursing, Medical device, Park So-yeon

NEW YORK, Sept. 28, 2023 /PRNewswire/ -- CurePSP has awarded its latest Pathway and Pipeline Grants and Urso Student Fellowships, totaling over $422,000. Recipients of the grants are: Dr. Kurt Farrell, assistant professor at the Icahn School of Medicine at Mount Sinai; Dr. Blas Couto, researcher at the Institute of Translational and Cognitive Neuroscience (INCyT) in Buenos Aires; Dr. Luana Fioriti, head of laboratory at the Mario Negri Institute for Pharmacological Research in Milan, alongside Dr. Carmela Tartaglia, associate professor at the University of Toronto and clinician at the Rossy PSP Centre; and Dr. Joseph B. Rayman, assistant professor of medical sciences at Columbia University Irving Medical Center. Recipients of the Urso Student Fellowship Grants are: Hania Qamar (mentor: Dr. Naomi Visanji), a graduate student at the University of Toronto; Hasnat Nuri (mentor: Dr. Stewart Clark), an undergraduate student at SUNY at Buffalo; and Soyeon Park (mentor: Dr. Jonathan Lin), an undergraduate student at Stanford University. The studies will make progress in identifying biomarkers, studying pathways for therapeutics and creating a new database of patients in Argentina.

Key Points: 
  • NEW YORK, Sept. 28, 2023 /PRNewswire/ -- CurePSP has awarded its latest Pathway and Pipeline Grants and Urso Student Fellowships, totaling over $422,000.
  • Recipients of the Urso Student Fellowship Grants are: Hania Qamar (mentor: Dr. Naomi Visanji), a graduate student at the University of Toronto; Hasnat Nuri (mentor: Dr. Stewart Clark), an undergraduate student at SUNY at Buffalo; and Soyeon Park (mentor: Dr. Jonathan Lin), an undergraduate student at Stanford University.
  • The studies will make progress in identifying biomarkers, studying pathways for therapeutics and creating a new database of patients in Argentina.
  • The newest Urso Student Fellowship grants were awarded to students conducting projects that focus on the complex barriers facing research of PSP and CBD.

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Retrieved on: 
Wednesday, September 27, 2023
Molecule, Abstract, Society, Therapy, Cancer, SITC, Immunotherapy, Tumor microenvironment, Neoplasm, Immunity, Annual general meeting, Poster, Vaccine

Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations at SITC annual meeting

Key Points: 
  • Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations at SITC annual meeting
    WATERTOWN, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the publication of abstracts for upcoming poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego, California.
  • Posters will be on display as follows:
    Title: Optimal Antitumor Immunity Triggered by WTX-124, a Clinical Stage Conditionally Activated INDUKINE™ Molecule that Releases Fully Potent IL-2 in the Tumor Microenvironment

WGL Energy Selects Molecule's ETRM Platform for Managing Gas, Power, and Renewables

Retrieved on: 
Wednesday, September 27, 2023
Hive, Government, Guarantee of origin, Risk management, WGL, Electra, Energy, FTR Moto, ETRM, Cryptocurrency, Molecule

HOUSTON, Sept. 27, 2023 /PRNewswire/ -- Molecule Software, the leader in modern cloud-based trading and risk management software for energy and commodities, announced that they were selected by WGL Energy Services (WGL Energy), as the retail energy supplier's energy trading risk management (ETRM) platform.

Key Points: 
  • WGL Energy Services chooses Molecule for modern ETRM capabilities designed for today's energy trading marketplace.
  • HOUSTON, Sept. 27, 2023 /PRNewswire/ -- Molecule Software, the leader in modern cloud-based trading and risk management software for energy and commodities, announced that they were selected by WGL Energy Services (WGL Energy), as the retail energy supplier's energy trading risk management (ETRM) platform.
  • WGL Energy is a leader in competitive energy supply and environmentally-friendly energy offerings in the Mid-Atlantic for residential, government, commercial, and industrial customers.
  • WGL Energy began evaluating solutions to replace an incumbent legacy ETRM system, which had been in place since 2006.

Global Contrast-Enhanced Ultrasound Market Set to Reach $2.1 Billion by 2028, Driven by Rising Geriatric Population and Research Activities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 26, 2023
Medical Devices, Health, Molecule, Equipment, CVD, GE HealthCare, Prevalence, Canon Inc., Bayer, Liver, Diagnosis, Software, Research, USD, Microbubble, Siemens Healthineers, Hospital, Investment, Conditional sentence, Growth, Abdominal ultrasonography, Region, Medical imaging, Pharmaceutical industry, Kidney

The global contrast-enhanced ultrasound market is projected to experience substantial growth, reaching USD 2.1 billion by 2028, up from USD 1.6 billion in 2023, with a CAGR of 6.1% from 2023 to 2028.

Key Points: 
  • The global contrast-enhanced ultrasound market is projected to experience substantial growth, reaching USD 2.1 billion by 2028, up from USD 1.6 billion in 2023, with a CAGR of 6.1% from 2023 to 2028.
  • Key factors driving this growth include the rising geriatric population and increased usage of contrast agents.
  • Additionally, growing research and development activities, government initiatives, and a rising number of clinical trials are contributing to the expansion of the contrast-enhanced ultrasound market.
  • The Asia Pacific region is expected to witness the highest growth in the contrast-enhanced ultrasound market during the forecast period.

"Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery"

Retrieved on: 
Monday, September 25, 2023
Molecule, University, D, Kidney, Household & Commercial Products Association, Cancer, Hope, Research, University of Science and Technology of China, Patient, File, School, Quality control, Exosome, FDA, Therapy, IND, NMPA, Targeted drug delivery, Autoimmunity, Medicine, Vaccine, Southeast University

SHENZHEN, China, Sept. 25, 2023 /PRNewswire/ -- On September 15, "Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery" successfully kicked off.

Key Points: 
  • SHENZHEN, China, Sept. 25, 2023 /PRNewswire/ -- On September 15, "Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery" successfully kicked off.
  • The forum focused on LNP- and extracellular vesicle-based drug delivery systems covering topics such as development trend, clinical research, process development, novel system design, and ideas on innovation.
  • Guided by platform-based corporate strategy "Innovation + Internationalization", Kexing Biopharm has formulated R&D plans emphasizing "Molecule Generation", "NMPA/FDA dual IND Filing" and "Out-licensing".
  • In 2021, Kexing Biopharm partnered with Southeast University to establish the "Innovation Laboratory for Commercial Production of Extracellular Vesicle-based Drug Delivery Technology".

"Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery"

Retrieved on: 
Monday, September 25, 2023
Molecule, University, D, Kidney, Household & Commercial Products Association, Cancer, Hope, Research, University of Science and Technology of China, Patient, File, School, Quality control, Exosome, FDA, Therapy, IND, NMPA, Targeted drug delivery, Autoimmunity, Medicine, Vaccine, Southeast University

SHENZHEN, China, Sept. 25, 2023 /PRNewswire/ -- On September 15, "Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery" successfully kicked off.

Key Points: 
  • SHENZHEN, China, Sept. 25, 2023 /PRNewswire/ -- On September 15, "Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery" successfully kicked off.
  • The forum focused on LNP- and extracellular vesicle-based drug delivery systems covering topics such as development trend, clinical research, process development, novel system design, and ideas on innovation.
  • Guided by platform-based corporate strategy "Innovation + Internationalization", Kexing Biopharm has formulated R&D plans emphasizing "Molecule Generation", "NMPA/FDA dual IND Filing" and "Out-licensing".
  • In 2021, Kexing Biopharm partnered with Southeast University to establish the "Innovation Laboratory for Commercial Production of Extracellular Vesicle-based Drug Delivery Technology".

Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology

Retrieved on: 
Monday, September 25, 2023
Molecule, Oncology, Partnership, Drug design, Development, Cancer, Drug discovery, Health care, R, Pharmaceutical industry, Research

This research will be combined with the oncology experience of Pierre Fabre Laboratories to identify drug candidates for treatment of a range of cancers for further development and commercialisation by Pierre Fabre Laboratories.

Key Points: 
  • This research will be combined with the oncology experience of Pierre Fabre Laboratories to identify drug candidates for treatment of a range of cancers for further development and commercialisation by Pierre Fabre Laboratories.
  • The research at Vernalis will be funded by Pierre Fabre Laboratories who will also pay research and clinical milestones and royalties on marketed products.
  • We look forward to building this long-term partnership with Pierre Fabre Laboratories, leveraging their deep expertise in cancer biology and clinical development."
  • Francesco Hofmann, Head of Research and Development for Medical Care at Pierre Fabre Laboratories said: "Partnering with Vernalis represents an important milestone for us.

Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology

Retrieved on: 
Monday, September 25, 2023
Molecule, Oncology, Partnership, Drug design, Development, Cancer, Drug discovery, Health care, R, Pharmaceutical industry, Research

This research will be combined with the oncology experience of Pierre Fabre Laboratories to identify drug candidates for treatment of a range of cancers for further development and commercialisation by Pierre Fabre Laboratories.

Key Points: 
  • This research will be combined with the oncology experience of Pierre Fabre Laboratories to identify drug candidates for treatment of a range of cancers for further development and commercialisation by Pierre Fabre Laboratories.
  • The research at Vernalis will be funded by Pierre Fabre Laboratories who will also pay research and clinical milestones and royalties on marketed products.
  • We look forward to building this long-term partnership with Pierre Fabre Laboratories, leveraging their deep expertise in cancer biology and clinical development."
  • Francesco Hofmann, Head of Research and Development for Medical Care at Pierre Fabre Laboratories said: "Partnering with Vernalis represents an important milestone for us.

Wistar Researchers Discover Possible New Treatment for Triple-Negative Breast Cancer

Retrieved on: 
Tuesday, September 19, 2023
TNBC, CRISPR, PBCC, Cell biology, University, Molecule, Nature Cancer, ACSS2, Culture, Genomics, DP2, HER2, Wistar, Breast, Infection, HIC, Cancer, Biomedical Research, Immunity, Jim Valvano, Research, Zhug, Bangladesh Technical Education Board, Ellen, National Cancer Institute, Triple-negative breast cancer, Patient, Metabolism, Wistar Institute, Immune system, University of Bologna, NCI, P30, NIH, Breast cancer, Vaccine

Schug’s paper — titled, “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer” — demonstrates a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer.

Key Points: 
  • Schug’s paper — titled, “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer” — demonstrates a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer.
  • Triple-negative breast cancer, or TNBC, affects 10-15% of patients with breast cancer in the US.
  • The absence of any of these receptors — receptors that, when present in other forms of breast cancer, can be effectively targeted during treatment — makes treating TNBC quite difficult, and patients with TNBC have limited treatment options.
  • TNBC’s notorious aggression makes the technical challenge of finding a reliably effective treatment target all the more serious: compared to other breast cancers, TNBC grows faster and resists treatment more stubbornly.

Depixus to showcase unique single molecule technology solving the hit-to-lead challenge in RNA-targeted drug discovery at upcoming Discovery on Target Conference

Retrieved on: 
Wednesday, September 20, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Molecule, Drug discovery, Ligand, RNA, Failure, Drug development, Conference, Pharmaceutical industry

Dr Gordon Hamilton, President & CEO of Depixus SAS, will be showcasing the company’s pioneering approach to transform RNA-targeted drug discovery at the upcoming Cambridge Healthtech Institute Discovery on Target Conference in Boston, USA, between 25 and 28 September 2023.

Key Points: 
  • Dr Gordon Hamilton, President & CEO of Depixus SAS, will be showcasing the company’s pioneering approach to transform RNA-targeted drug discovery at the upcoming Cambridge Healthtech Institute Discovery on Target Conference in Boston, USA, between 25 and 28 September 2023.
  • Progress in this space is hampered by a lack of effective methods to visualize and understand how RNA structures interact with their native ligands and candidate drugs.
  • This major limitation can result in ineffective molecules being advanced through the drug development pipeline with consequent costly failure during late preclinical or early clinical stages.
  • Based on magnetic force spectroscopy, Depixus’ MAGNA™ technology enables high-throughput single molecule analysis of molecular interactions between small molecules and target RNAs in near-real time.